Copyright
©The Author(s) 2021.
World J Gastroenterol. Jul 28, 2021; 27(28): 4504-4535
Published online Jul 28, 2021. doi: 10.3748/wjg.v27.i28.4504
Published online Jul 28, 2021. doi: 10.3748/wjg.v27.i28.4504
Table 4 Outcome of the patients with severe elevation of aminotransferases in coronavirus disease 2019
| Ref. | Outcome of patients | SARS-CoV-2 patients with hypertransaminasemia (n = 20) | COVID-19 patients without hypertransaminasemia (n = 125) | P value |
| Ramachandran et al[169], 2020 | Shock | 9 (45%) | 38 (30.4%) | 0.207 |
| Mechanical ventilation | 10 (50%) | 30 (24%) | 0.028 | |
| Died | 10 (50%) | 46 (36.8%) | 0.324 | |
| Length of stay in days, median (IQR) | 7 (4.3, 10.3) | 7 (5, 10) | 0.78 |
- Citation: Mohamed DZ, Ghoneim MES, Abu-Risha SES, Abdelsalam RA, Farag MA. Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management. World J Gastroenterol 2021; 27(28): 4504-4535
- URL: https://www.wjgnet.com/1007-9327/full/v27/i28/4504.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i28.4504